Myofascial Pain Syndrome
Conditions
Brief summary
The patients will be randomly assigned to one of the two groups according to the treatment method: group I (masseter group) and group II (masseter &sternocleidomastoid group) where each patient will be injected 0.5ml in each trigger point (TrPs) of magnesium sulphate according to the treatment group by the same operator. The treatment method for TrPs will be the primary predictor variable. Patients will be examined at the following intervals: during diagnosis, 1-month, 3-months, and 6-months post-injection. The participated patients will be assessed using pain score measured on a 10-point visual analogue scale (VAS), the 0 indicating no pain and 10 indicating the worst pain ever
Interventions
DRUGmasseter muscle
masseter muscle trigger points injection by magnesium sulphate
DRUGmasseter and sternocleidomastoid muscle
masseter and sternocleidomastoid muscle trigger points injection by magnesium sulphate
Sponsors
Fayoum University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* definite diagnosis of myofascial pain * presence of one or more unilateral or bilateral trigger points in the masseter muscle and sternocleidomastoid muscle; * no history of any invasive procedures of the related masseter muscle.
Exclusion criteria
* any painful conditions (other than myofascial trigger points) affecting the orofacial region * any systemic diseases that could masticatory function (e.g., rheumatoid arthritis and epilepsy); * pregnancy and lactation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| muscle pain | 6 months | by visual analogue scal |
Outcome results
None listed